Objectives: Chronic kidney disease (CKD) increases in the general population and is associated with high mortality. Diagnosis of CKD relies on serum creatinine which needs blood sampling and can be affected by factors unrelated to renal function. Therefore, we aimed to explore potential breath biomarkers to identify normal from CKD through thermal desorption-gas chromatography mass-spectrometry (TD-GCMS).  Methods: Untargeted metabolomics using TD-GCMS was performed on breath samples from normal healthy controls (n=10), non-dialysis CKD patients (n=21), and end-stage renal disease (ESRD) patients on hemodialysis (n=12).  Results:  Metabolomic analysis revealed sixty-eight significantly different volatile organic compounds (VOCs) in breath of CKD patients (non-dialysis CKD + ESRD) compared to normal healthy controls by using T-test. In the univariate analysis, a total of twenty-nine VOCs were revealed significantly different in the CKD patients compared to normal healty controls. Multivariate model which incorporated 2,6-dimethyloctane [OR  10.6 (95% CI: 2.28-154.08), p = 0.022], octanal [OR 10.3 (95% CI: 1.45-240.65), p = 0.056] and benzaldehyde [OR 5.54 (95% CI: 1.21-60.24), p = 0.067] showed high performance in identifying CKD patients (AUROC = 0.967).  Conclusions: In conclusion, this study showed breath VOCs may be used as non-invasive potential biomarkers in screening test for CKD.